Pimecrolimus
- Generic Name
- Pimecrolimus
- Brand Names
- Elidel
- Drug Type
- Small Molecule
- Chemical Formula
- C43H68ClNO11
- CAS Number
- 137071-32-0
- Unique Ingredient Identifier
- 7KYV510875
Overview
Pimecrolimus is an immunomodulating agent that was first marketed by Novartis under the trade name Elidel. It is now promoted in Canada by Galderma since early 2007. It is currently available as a topic cream used in the treatment of atopic dermatitis (eczema).
Background
Pimecrolimus is an immunomodulating agent that was first marketed by Novartis under the trade name Elidel. It is now promoted in Canada by Galderma since early 2007. It is currently available as a topic cream used in the treatment of atopic dermatitis (eczema).
Indication
For treatment of mild to moderate atopic dermatitis.
Associated Conditions
- Vitiligo
- Intertriginous psoriasis
- Mild Atopic dermatitis
- Moderate Atopic dermatitis
Clinical Trials
FDA Approved Products
Pimecrolimus
Manufacturer:Bryant Ranch Prepack
Route:TOPICAL
Strength:10 mg in 1 g
Approved: 2024/03/21
NDC:72162-1889
Elidel
Manufacturer:Physicians Total Care, Inc.
Route:TOPICAL
Strength:10 mg in 1 g
Approved: 2010/08/31
NDC:54868-4878
Pimecrolimus
Manufacturer:Glenmark Pharmaceuticals Inc., USA
Route:TOPICAL
Strength:10 mg in 1 g
Approved: 2018/11/11
NDC:68462-609
Pimecrolimus
Manufacturer:Bryant Ranch Prepack
Route:TOPICAL
Strength:10 mg in 1 g
Approved: 2024/03/22
NDC:72162-1891
Pimecrolimus
Manufacturer:Oceanside Pharmaceuticals
Route:TOPICAL
Strength:10 mg in 1 g
Approved: 2020/09/30
NDC:68682-110
Singapore Approved Products
ELIDEL CREAM 1% w/w
Manufacturer:NOVARTIS PHARMA PRODUKTIONS GMBH, MEDA Manufacturing
Form:CREAM
Strength:10 mg/g
Online:Yes
Approved: 2003/01/31
Approval:SIN12179P
Drug Development Updates
Stay informed with timely notifications on clinical trials and research advancements.
© Copyright 2025. All Rights Reserved by MedPath